FDAnews
www.fdanews.com/articles/61674-sami-labs-receives-dcgi-approval-for-ocufors-drug-for-glaucoma-care

SAMI LABS RECEIVES DCGI APPROVAL FOR OCUFORS DRUG FOR GLAUCOMA CARE

August 14, 2006

Sami Labs, the herbal nutraceutical major, has received the permission from the Drugs Controller General of India to manufacture and market the new drug for Glaucoma developed from Forskolin that is a one percent ophthalmic solution. The drug will be sold under the brand name Ocufors. In India, the market for Glaucoma drugs is estimated to be around Rs 100 crore and Sami is gearing up to grab a 10 per cent market share. The company is also in the process of seeking international registrations in Europe, US and Australia. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34649ionid=) (http://www.keralanext.com/news/index.asp?id=805965)